Its objectives are threefold: first, to estimate the pooled prevalence of cognitive impairment among individuals with CSVD; second, to evaluate associations between MRI-based CSVD markers and cognitive outcomes; and third, to assess the impact of genetic risk factors, particularly the APOE ε4 allele, on cognitive impairment in CSVD populations. The gene discussed is APOE; the disease is Cognitive impairment.